Plan B in HCV

After Inhibitex: BMS hopes it is back in running with triple oral combo in HCV

Bristol-Myers Squibb Co.'s HCV ambitions did not die with Inhibitex Inc.'s INX-189. The pharma believes its next choice for all-oral regimen involving NS3 protease, NS5A protein and non-nucleoside NS5B inhibitors has the safety and convenience to compete with more advanced rivals in HCV genotype 1 infection.

Last week, BMS said the triple combination achieved competitive SVR rates in a Phase IIa trial.

When INX-189 (BMS-986094) imploded last August, it seemed to leave a hole in BMS's HCV portfolio based on the conventional wisdom that a nucleoside NS5B polymerase inhibitor must be the backbone of an all-oral, interferon-free HCV regimen (see BioCentury, Sept. 10, 2012).

Moreover, the competition would be stretching out its lead.

Sofosbuvir

Read the full 1104 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE